Simulations Plus, Inc. (NASDAQ:SLP) Receives $17.25 Average PT from Analysts

Simulations Plus, Inc. (NASDAQ:SLP) has been given a consensus rating of “Reduce” by the eight brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation and seven have assigned a hold recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $17.25.

A number of equities research analysts have issued reports on SLP shares. Weiss Ratings upgraded shares of Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 10th. William Blair cut shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 17th. Wall Street Zen downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Finally, Craig Hallum lowered Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price objective for the company. in a report on Thursday, June 18th.

Insider Buying and Selling

In other Simulations Plus news, Director Walter S. Woltosz sold 4,177 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $18.44, for a total value of $77,023.88. Following the transaction, the director directly owned 3,202,131 shares of the company’s stock, valued at $59,047,295.64. This represents a 0.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Simulations Plus

Several institutional investors have recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in shares of Simulations Plus in the 2nd quarter valued at approximately $25,000. Quarry LP bought a new position in Simulations Plus during the third quarter valued at approximately $28,000. GAMMA Investing LLC raised its position in Simulations Plus by 26.0% during the second quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock valued at $52,000 after acquiring an additional 585 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Simulations Plus by 343.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company’s stock valued at $73,000 after acquiring an additional 3,084 shares during the last quarter. Finally, Longfellow Investment Management Co. LLC acquired a new stake in Simulations Plus in the second quarter valued at approximately $77,000. 78.08% of the stock is currently owned by institutional investors and hedge funds.

Simulations Plus Price Performance

NASDAQ:SLP opened at $18.43 on Monday. Simulations Plus has a fifty-two week low of $11.09 and a fifty-two week high of $21.01. The stock’s 50-day moving average is $18.32 and its two-hundred day moving average is $15.54. The stock has a market cap of $372.84 million, a PE ratio of 46.07 and a beta of 1.33.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.07. Simulations Plus had a net margin of 9.88% and a return on equity of 13.50%. The business had revenue of $21.89 million during the quarter, compared to analyst estimates of $20.90 million.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.